资源类型:
期刊
Pubmed体系:
Journal Article;Review
文章类型:
论著
机构:
[1]Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, Shaanxi, China.
[2]Department of Urology, First Affiliated Hospital of Kunming Medical University, Kunming 65000, Yunnan, China.
外科科室
泌尿外科
昆明医科大学附属第一医院
[3]College of Life Sciences, Northwest University, Xi'an 710068, Shaanxi, China.
[4]School of Clinical Medicine, Xi'an Medical University, Xi'an 710021, Shaanxi, China.
关键词:
Bladder cancer
advanced urothelial carcinoma
targeted therapy
combination therapy
molecular alteration
摘要:
Bladder cancer (BC) is the tenth most common malignancy globally. Urothelial carcinoma (UC) is a major type of BC, and advanced UC (aUC) is associated with poor clinical outcomes and limited survival rates. Current options for aUC treatment mainly include chemotherapy and immunotherapy. These options have moderate efficacy and modest impact on overall survival and thus highlight the need for novel therapeutic approaches. aUC patients harbor a high tumor mutation burden and abundant molecular alterations, which are the basis for targeted therapies. Erdafitinib is currently the only Food and Drug Administration (FDA)-approved targeted therapy for aUC. Many potential targeted therapeutics aiming at other molecular alterations are under investigation. This review summarizes the current understanding of molecular alterations associated with aUC targeted therapy. It also comprehensively discusses the related interventions for treatment in clinical research and the potential of using novel targeted drugs in combination therapy.© The Author(s) 2024.
基金:
This study was supported by the Shaanxi Province Key Industry Chain Project [2022ZDLSF05-14].
PubmedID:
38966172
第一作者:
Shang Shihao
第一作者机构:
[1]Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, Shaanxi, China.
共同第一作者:
Zhang Lei;Liu Kepu
通讯作者:
Yuan Jianlin;Zhu Zheng
推荐引用方式(GB/T 7714):
Shang Shihao,Zhang Lei,Liu Kepu,et al.Landscape of targeted therapies for advanced urothelial carcinoma[J].Exploration Of Targeted Anti-Tumor Therapy.2024,5(3):641-677.doi:10.37349/etat.2024.00240.
APA:
Shang Shihao,Zhang Lei,Liu Kepu,Lv Maoxin,Zhang Jie...&Zhu Zheng.(2024).Landscape of targeted therapies for advanced urothelial carcinoma.Exploration Of Targeted Anti-Tumor Therapy,5,(3)
MLA:
Shang Shihao,et al."Landscape of targeted therapies for advanced urothelial carcinoma".Exploration Of Targeted Anti-Tumor Therapy 5..3(2024):641-677